Literature DB >> 16521205

Five-year survival following a medial pancreatectomy for an invasive ductal carcinoma from the body of the pancreas.

Hideki Abe1, Kouichi Tsuneyama, Kazuhiro Tsukada, Masatoshi Makuuchi.   

Abstract

We report a rare case of a patient who survived for 5 years after undergoing a medial pancreatectomy for invasive ductal carcinoma originating from the body of the pancreas. A 63-year-old woman was diagnosed as a small cancer of the pancreatic body, and surgery was performed. Even though the tumor was a carcinoma, its small size prompted us to perform a medial pancreatectomy with regional lymph nodes dissection. Additional chemoradiation was performed and, five years after surgery, the patient is well with no signs of recurrence. Medial pancreatectomy for invasive ductal carcinoma has not ever been reported. Furthermore, long-term survival after a lumpectomy for invasive ductal carcinoma has never been reported in the literatures. The current case suggests that long-term survival in patients with invasive ductal carcinoma of the pancreas may be associated with the pathological or biological features of pancreatic carcinoma.

Entities:  

Mesh:

Year:  2006        PMID: 16521205      PMCID: PMC4066142          DOI: 10.3748/wjg.v12.i5.822

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  7 in total

Review 1.  Adjuvant or neoadjuvant therapy for pancreatic carcinoma?

Authors:  J Jeekel
Journal:  Digestion       Date:  1997       Impact factor: 3.216

Review 2.  Treatment of pancreatic cancer: the role of surgery.

Authors:  F Ozawa; H Friess; B Künzli; S V Shrikhande; T Otani; M Makuuchi; M W Büchler
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

3.  Medial pancreatectomy for tumors of the neck of the pancreas.

Authors:  N Rotman; B Sastre; P L Fagniez
Journal:  Surgery       Date:  1993-05       Impact factor: 3.982

4.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

5.  Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy.

Authors:  J G Fortner; D S Klimstra; R T Senie; B J Maclean
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

6.  CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.

Authors:  Akira Fukunaga; Masaki Miyamoto; Yasushi Cho; Soichi Murakami; You Kawarada; Taro Oshikiri; Kentaro Kato; Takanori Kurokawa; Masato Suzuoki; Yoshihiro Nakakubo; Kei Hiraoka; Tomoo Itoh; Toshiaki Morikawa; Shunichi Okushiba; Satoshi Kondo; Hiroyuki Katoh
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

7.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors.

Authors:  K C Conlon; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.